Viking Therapeutics: Obesity Pipeline Matures with New Amylin Program and Maintenance Data on the Horizon
Q2 2026 update shows continued execution on VK2735 Phase III and a fresh clinical candidate, but the real excitement is the upcoming maintenance study readout.
VKTX · Earnings Call · 2026-07-29
A Quarter of Quiet Progress
Viking Therapeutics' Q2 2026 call read like a company hitting its marks. “During the second quarter, we continued to advance each of the programs within our expanding obesity franchise” — Brian Lian, Chief Executive Officer · 2026-07-29 — a statement that belies the fact that this franchise is about to hit a major inflection point. The dual GLP-1/GIP agonist GLP 1 program, VK2735, is now fully enrolled across both Phase III VANQUISH studies, and the oral tablet formulation is set to begin its own Phase III program in Q4. But the most anticipated event is the maintenance trial readout, expected "later this quarter," which could redefine how obesity drugs are dosed.
Maintenance: The Differentiator
Management has repeatedly framed the maintenance study as a potential game-changer. In the current call, Brian Lian noted: “The maintenance study leverages VK2735's unique in vivo profile and will assess the effects of weekly, monthly and every other week regimens to identify those that may best support the individualized and long-term care often required to achieve and sustain a healthy weight.” — Brian Lian, Chief Executive Officer · 2026-07-29 The idea is that a dual agonist with a long half-life can be transitioned to less frequent dosing while preserving weight loss. This continues a theme from prior quarters — in February, Lian told analysts: “We look at 3, I guess, major buckets there. Everybody titrates up to this high weekly level. And then you have some people transitioning to monthly injections, some transitioning to every other week injections...” — Brian Lian, President and Chief Executive Officer · 2026-02-11 The 12-week maintenance window may be short, but it will inform the design of VANQUISH extension studies.
We expect to report the results of this study later this quarter.
If the data support monthly or biweekly maintenance, Viking could leapfrog competitors in patient convenience — a key commercial lever as the obesity market grows increasingly crowded.
New Program: VK3019
The other headline was the initiation of Phase I for VK3019, a dual amylin and calcitonin receptor agonist. In the prepared remarks, Lian said: “During the second quarter, Viking expanded its clinical stage obesity portfolio with the initiation of a Phase I single ascending dose trial of VK3019 an investigational dual amylin and calcitonin receptor agonist.” — Brian Lian, Chief Executive Officer · 2026-07-29 This molecule has shown potent preclinical efficacy — including greater weight loss than VK2735 in obese primates — and positions Viking to explore combinations. The VK3019 keyword spiked to the top of the company's mover list this quarter (momentum 239), reflecting investor excitement about pipeline breadth beyond the lead asset. As Lian explained in the Q&A, the mechanism could serve as a monotherapy for patients intolerant to GLP-1s or as an add-on combo: “When you add amylin onto a GLP-1, you typically see 40% to 50% improvement in efficacy.” — Brian Lian, Chief Executive Officer · 2026-07-29
The Cost of Ambition
All this progress comes at a price. R&D expenses for the quarter were $115.8M, up from $60.2M a year ago, in line with the Phase III expansion. The company's net loss widened to $128.1M, and the balance sheet shows R&D expenses hit $150M in Q1 2026, a 263% YoY increase. Cash at quarter-end stood at $502M, down from $706M at year-end. CFO Greg Zante addressed the burn rate directly: “I think the cash usage will start to go down a bit, taper a bit from here, certainly next year versus this year.” — Gregory Zante, Chief Financial Officer · 2026-07-29 The company maintains that existing cash covers all three major catalysts — maintenance data, Phase III subcu readout, and oral Phase III initiation — into 2028.
What to Watch
The next 90 days are pivotal. In addition to the maintenance data, the oral Phase III program is expected to kick off in Q4, a study that management suggests will be smaller and more efficient than the subcutaneous VANQUISH. If the maintenance results show durable weight loss with monthly or biweekly dosing, and the oral program advances smoothly, Viking could be positioned as the only player with both a best-in-class injectable and an oral dual agonist, plus a potential combo partner in calcitonin receptor agonist VK3019. The tape reflects this optimism — the stock has been flat over the past 90 days while building a base near its recent high, a sign that institutional investors are waiting for a catalyst rather than abandoning the name.
All in all, this was a "steady as she goes" quarter, but the upcoming data will determine whether Viking's story is merely good or truly transformative.